Editorials
Why do cancer drugs get such an easy ride?
BMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h2068 (Published 23 April 2015) Cite this as: BMJ 2015;350:h2068
Related articles
- Research Published: 23 September 2015; BMJ 351 doi:10.1136/bmj.h4633
- Analysis Published: 23 October 2015; BMJ 351 doi:10.1136/bmj.h5542
- Research Published: 18 September 2019; BMJ 366 doi:10.1136/bmj.l5221
See more
- NHS should vary price it pays for cancer drugs to improve access, say expertsBMJ November 09, 2020, 371 m4322; DOI: https://doi.org/10.1136/bmj.m4322
- Colon cancer screening should begin at 45, says US task forceBMJ October 29, 2020, 371 m4188; DOI: https://doi.org/10.1136/bmj.m4188
- Leading oncologist faces GMC allegations of inappropriate treatment of dying patientsBMJ September 15, 2020, 370 m3594; DOI: https://doi.org/10.1136/bmj.m3594
- Covid-19: Waiting times in England reach record highsBMJ September 11, 2020, 370 m3557; DOI: https://doi.org/10.1136/bmj.m3557
- Trial to extend breast cancer screening won’t resume randomisation after pandemicBMJ August 26, 2020, 370 m3337; DOI: https://doi.org/10.1136/bmj.m3337
Cited by...
- Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis
- Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval?
- Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014
- Why the drug development pipeline is not delivering better medicines
- The FDA's new clothes
- Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study